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Ventricular assist devices (VADs) are playing a large role in
the management of end-stage heart failure. Approximately
35% of patients with a VAD have ventricular arrhythmias
within the ﬁrst month of implantation.1 Electrophysiologic
ablations in the setting of a VAD are limited to left VADs
(LVADs). To our knowledge, we describe the ﬁrst report of
ablation of a hemodynamically signiﬁcant ventricular tachy-
cardia in a patient with a biventricular assist device
(BiVAD).Case report
A 63-year-old female with a history of nonischemic cardi-
omyopathy underwent implantation of a HeartWare LVAD
(Framingham, MA) in June 2013, but postoperatively
developed severe right ventricular (RV) heart failure and
underwent HeartWare RVAD placement. In February 2014,
the patient presented with recurrent presyncope due to
sustained ventricular tachycardia (VT). Despite the use of
multiple antiarrhythmic drugs, multiple cardioversions, and
changes in RV and left ventricular inlet ﬂows, the patient
continued to have recurrent, sustained VT, leading to
hemodynamic compromise. The sustained VT caused a
decrease in mean arterial blood pressure by roughly 10
mm Hg and decreased BiVAD cannulae ﬂows.
Because of sustained and symptomatic VT despite
biventricular support, the patient was taken for electro-
physiologic study and VT ablation. The clinical VT had a
cycle length of 300 milliseconds, with axis and precordialKEYWORDS Ventricular tachycardia; Catheter ablation; Biventricular assist
device; Ventricular assist device
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Extensive mapping was performed in the right ventricle.
Overdrive pacing in the right ventricle at presystolic sites
near the RV inlet cannula led to good pace maps of the VT
with a postpacing interval minus tachycardia cycle length of
14 milliseconds (Figure 2A). Neither broad activation
mapping to suggest a macroreentrant circuit nor maneuvers
to demonstrate progressive fusion were performed, so it is
unclear if the VT mechanism was focal or reentrant. Catheter
ablation was performed at this site using a ThermoCool SF
catheter (Biosense Webster, Diamond Bar, CA) at 35 W with
a maximum temperature of 401C. Twenty-ﬁve seconds into
ablation, the VT terminated (Figure 2B). Further ablation
was performed in this region, toward the RV inlet cannula
(Figure 3). VT was noninducible despite triple extrastimuli
and changes in RV inlet ﬂow (previously this method had
reproducibly induced the clinical VT). Mapping of the left
ventricle was not performed, as the arrhythmia was not
inducible after termination. Afterward, administration of the
antiarrhythmic agents lidocaine, amiodarone, and proprano-
lol was discontinued. At similar pump speeds, the RVAD
pump ﬂow increased from 4.4 L/min to 5 L/min and the
LVAD pump ﬂow increased from 3.5 L/min to 5 L/min
postablation. The patient was symptom free in subsequent
follow-up clinic visits, and she underwent successful heart
transplantation in June 2014. Direct visualization of the
explanted heart showed extensive scarring within the right
ventricle in the region of successful ablation.
Discussion
Ventricular arrhythmias are known to occur after LVAD
implantation.2 Although initial reports suggest that ventric-
ular arrhythmias may be tolerated in patients with LVADs,3
prolonged of RV failure, thrombus formation, or decreased
ﬂows via the LVAD may lead to undesired consequences.
Further, recent data have suggested that ventricular arrhyth-
mias post–LVAD implantation in this patient population
may be associated with increased mortality.4 Given these
considerations, catheter ablation for patients with LVAD has
been reported.1,5pen access article under the CC BY-NC-SA license
http://dx.doi.org/10.1016/j.hrcr.2015.02.015
KEY TEACHING POINTS
 Patients with left ventricular assist devices can
develop hemodynamically signiﬁcant ventricular
tachycardia.
 Catheter ablation can be safely performed in
patients with ventricular tachycardia and
ventricular assist devices.
 Ventricular tachycardia may cause hemodynamic
sequelae even in patients with biventricular assist
devices.
Heart Rhythm Case Reports, Vol 1, No 4, July 2015210Traditionally, with BiVAD support, ventricular arrhyth-
mias are generally tolerated given both RV and left
ventricular support. Refaat et al6 reported no difference in
survival to transplant in BiVAD patients with an implantable
cardioverter-deﬁbrillator. We, however, report a case of
symptomatic, hemodynamically signiﬁcant VT despite
BiVAD support. Continuous ﬂow VADs are known to causeFigure 1 A 12-lead electrocardiogram“septal push,”which can induce VT from the inlet cannula as
it creates a suction effect against the myocardium. In our
patient, despite multiple changes in ﬂow rates, VT persisted.
The patient’s symptoms potentially were from lack of
pulsatile ﬂow in VT, as pulsatility was restored after
ablation, with improved BiVAD cannulae ﬂows. Given the
patient’s symptoms and that no donor heart was available,
the decision was made to pursue catheter ablation.
The successful site of ablation in this patient was near the
RV inlet cannula within the right ventricle. Although reentrant
VT can occur around an inlet cannula, intrinsic myocardial
scar–related VT has been the predominant mechanism reported
in LVAD patients.1,5 Entrainment maneuvers were not per-
formed around the various cannulae to elucidate if this VT was
focal or a reentrant one involving the RV, LV, or both inlet
cannulae. This patient had an underlying nonischemic cardio-
myopathy and electrocardiogram features suggestive of an
epicardial exit.7 Further, unipolar RV voltage mapping revealed
a large area of low voltage (o5.5 mV) in this region, also
suggestive of epicardial scar.8 This ﬁnding is potentially why
there was a delayed termination during ablation.of clinical ventricular tachycardia.
Figure 2 A: Overdrive pacing with postpacing interval–tachycardia cycle length of 14 milliseconds at the site of presystolic potentials, and B: delayed
termination during ablation at that site. Lines A1-2 and B2-3 reﬂect the right ventricular decapolar catheter. Abl D ¼ distal ablation; Abl P ¼ proximal ablation;
CS ¼ coronary sinus; RVd ¼ distal RV recording; RVp ¼ proximal RV recording; RF ¼ radiofrequency ablation.
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Figure 3 A: Right anterior oblique and B: left anterior oblique projections of the successful ablation site. The ablation catheter lies in the distal apicoseptal
right ventricle. Abl¼ ablation catheter; CS¼ coronary sinus catheter; LVIC¼ left ventricular inlet cannula; RV¼ right ventricular decapolar catheter; RVIC¼
right ventricular inlet cannula.
Heart Rhythm Case Reports, Vol 1, No 4, July 2015212In conclusion, despite biventricular VAD support,
patients may experience symptomatic ventricular tachycar-
dia, which could be effectively treated with catheter ablation.References
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